Theralase Technologies Inc. V.TLT

90, 180, 360.... CR% the same.

[wildbird1]

CR%(Complete Response)
According to TLT, comparing the 90 and 180 day data, demonstrate that once a patient has obtained CR(complete response) or PR(partial response), the duration of the response remain approxmimately the same.

The above indicate that if the 90 day CR is approximately the same at 180,360.... day, it will be very interesting to see if the FDA take the above into account and give Breakthrought Designation faster approval.

Shares out.
Right now TLT has 204 million shares out, and 57 million warrants(0.35$) from the last prospectus August 22,2019.
If exercised these warrants will bring the total to 261 million shares out, and $20 million more in  the Bank for TLT.
261 million shares out is still a puny little number of shares out for a company on the brink of finding a solution not only for Bladder Cancer but for many cancer.

Can't wait for the next 2 Quaterly Newsletter and the CR% at 90 and 180 day of all the optimized patients. The 180 day CR% will open a lot of eyes (including the FDA).

According to peoples on this board that have a better understanding of the Quaterly Newsletter numbers the CR% could easily be over 70%. 
70% CR(or more) is huge for a treatment that treat only " End Of The Line Patients".

[Pandora]

37.5 cent warrants expire November 5. Will they allow them to expire or will they extend them? That should be one news release for the beginning of the week.

[Pandora]

My apologies - I said November 5 expiry -- it should have said November 10 expiry.

[gojotv!]

As far as I'm concerned, anything over 30% CR is very exciting. For the purposes of this trial, only two treatments were given per patient. That makes sense, because you want to test over a broad cross-section of people, and keep trial costs down. But in the real world, with TLD-1433's negligible side effects, you can just keep treating... 3, 4 times... until it works. We're looking at

[CancerSlayer]

Gojotv! said: "As far as I'm concerned, anything over 30% CR is very exciting. For the purposes of this trial, only two treatments were given per patient. That makes sense, because you want to test over a broad cross-section of people, and keep trial costs down. But in the real world, with TLD-1433's negligible side effects, you can just keep treating... 3, 4 times... until it

[socksnblonds642]

Yup that 730 day+++ is the most exciting news. Those two patients appear to be cured. If the cancer ever does reappear or a patient has a more aggressive type then they get another treatment. Maybe they have ten treatments over over thirty years, maybe just one. As you say we are looking at the cure for cancer here. So far the numbers point very strongly towards that. Early days though. Next NR